In a significant relief for patients battling cancer and rare diseases, Finance Minister Nirmala Sitharaman announced in the Union Budget 2026-27 that the government will waive basic customs duty on 17 critical drugs and medicines. The move aims to make life-saving treatments more affordable and accessible to those in need.
Support for Rare Disease Patients
Beyond cancer, the government will extend import duty exemptions for medicines, drugs, and specialized medical foods brought in personally for the treatment of seven additional rare diseases. This expansion reflects the growing focus on inclusive healthcare and support for patients requiring specialized therapies.
Boosting Healthcare Infrastructure
Alongside the duty waivers, the Finance Minister highlighted plans to strengthen India’s medical research and treatment capabilities. Among these initiatives is the proposal to develop NIMHANS-2, a new facility aimed at expanding advanced neurological and mental health care services in the country.
Impact on Patients and Healthcare Ecosystem
Experts say the duty exemptions will significantly reduce treatment costs, especially for imported drugs that are often prohibitively expensive. Patients battling rare diseases, many of which require specialized and high-cost treatments, are expected to benefit immediately.
The announcement is part of a broader vision in Budget 2026 to improve healthcare accessibility, support domestic production, and integrate innovative solutions for both treatment and research in critical medical sectors.